Form 4: Director Marjorie Green Equity Transaction at NeoGenomics

Director Marjorie Green acquired 22,964 shares of NeoGenomics common stock through the vesting of restricted stock units.

Summary

• Director Marjorie Green exercised and settled 22,964 restricted stock units (RSUs) into common stock on June 1, 2026.
• The reporting person was granted new equity compensation consisting of 11,069 stock options at a strike price of $10.52 and 15,970 restricted stock units.
• The transaction reflects standard equity compensation vesting and new grant activity for a board member.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard director compensation and equity vesting rather than a strategic shift or market-driven trade.

Positives

• Director maintains a direct ownership stake in the company, aligning interests with shareholders.
• The acquisition of shares through RSU vesting indicates ongoing compensation-based equity accumulation.

Negatives

• None identified; this is a routine compensatory transaction.

Risks

• Equity-based compensation is subject to market volatility affecting the value of future grants.
• Performance-based vesting conditions for future grants may not be met.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of director equity transactions.

Industry Context

StockSavvy.ai notes that routine equity grants to board members are standard corporate governance practices in the biotechnology and diagnostics sector to ensure long-term alignment between directors and shareholders.

Comparison to Industry Standards

• The equity compensation structure is consistent with standard practices for mid-cap healthcare companies.
• The use of both stock options and RSUs is a common retention and incentive strategy for board members in the diagnostics industry.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine compensatory transaction.

Next Steps

• Vesting of the newly granted 11,069 stock options on 06/01/2027.
• Vesting of the newly granted 15,970 restricted stock units on 06/01/2027.

Key Dates

Keywords

NeoGenomics, NEO, Form 4, Insider Trading, Equity Compensation, Director Ownership